De novo peptide design and experimental validation of histone methyltransferase inhibitors

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Smadbeck, James ^a   Peterson, Meghan B ^a   Zee, Barry M ^b   Garapaty, Shivani ^c   Mago, Aashna ^b   Lee, Christina ^c   Giannis, Athanassios ^d   Trojer, Patrick ^c   Garcia, Benjamin A ^b,e   Floudas, Christodoulos A ^a  

^a Princeton University   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c Department of Structural Biology   (United States)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; PEPTIDE; SQ 010; SQ 011; SQ 020; SQ 025; SQ 026; SQ 032; SQ 035; SQ 037; SQ 040; SQ 043; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; ENZYMATIC ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MASS SPECTROMETRY; MATHEMATICAL COMPUTING; PROTEIN FOLDING; VALIDATION PROCESS;

AMINO ACID SEQUENCE; BINDING SITES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL NUCLEUS; DRUG DESIGN; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; KINETICS; LIGANDS; METHYLATION; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; PEPTIDES; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BINDING; PROTEIN FOLDING;

EID: 84896497750     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090095     Document Type: Article

References (48)

1. Shi Y, Whetstine JR (2007) Dynamic regulation of histone lysine methylation by demethylases. Mol Cell 25: 1-14. (Pubitemid 46049067)
2. Stavropoulos P, Blobel G, Hoelz A (2006) Crystal structure and mechanism of human lysine-specific demethylase-1. Nat Struct Mol Biol 13: 626-632. (Pubitemid 44036473)
3. Khoury GA, Baliban RC, Floudas CA (2011) Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. Sci Rep 1.
4. Mund C, Lyko F (2010) Epigenetic cancer therapy: Proof of concept and remaining challenges. BioEssays 32: 949-957.
5. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
6. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. P Natl Acad Sci USA 100: 11606-11611. (Pubitemid 37205983)
7. Sellers WR, Loda M (2002) The EZH2 polycomb transcriptional repressora marker or mover of metastatic prostate cancer? Cancer Cell 2: 349-350. (Pubitemid 41039099)
8. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res-Fund Mol M 647: 21-29.
9. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, et al. (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108-112.
10. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, et al. (2008) Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28: 843-853.
11. Spannhoff A, Sippl W, Jung M (2009) Cancer treatment of the future: Inhibitors of histone methyltransferases. Int J Biochem Cell B 41: 4-11.
12. Tan J, Yang X, Zhuang L, Jiang X, Chen W, et al. (2007) Pharmacologic disruption of polycombrepressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Gene Dev 21: 1050-1063. (Pubitemid 46686474)
13. Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, et al. (2009) Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther 8: 939-950.
14. Choudhury SR, Balasubramanian S, Chew YC, Han B, Marquez VE, et al. (2011) (2)- Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis 32: 1525-1532.
15. Diaz E, Machutta CA, Chen S, Jiang Y, Nixon C, et al. (2012) Development and validation of reagents and assays for EZH2 peptide and nucleosome highthroughput screens. J Biomol Screen 17: 1279-1292.
16. Qi W, Chan H, Teng L, Li L, Chuai S, et al. (2012) Selective inhibition of EZH2 by a small molecule inhibitor blocks tumor cells proliferation. P Natl Acad Sci USA 109: 21360-21365.
17. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, et al. (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8: 890-896.
18. Luo M (2012) Current chemical biology approaches to interrogate protein methyltransferases. ACS Chem Biol 7: 443-463.
19. Klepeis JL, Floudas CA, Morikis D, Tsokos CG, Argyropoulos E, et al. (2003) Integrated structural, computational and experimental approach for lead optimization: Design of compstatin variants with improved activity. J Am Chem Soc 125: 8422-8423. (Pubitemid 36858397)
20. Klepeis JL, Floudas CA, Morikis D, Tsokos CG, Lambris JD (2004) Design of peptide analogs with improved activity using a novel de novo protein design approach. Ind Eng Chem Res 43: 3817-3826. (Pubitemid 38859258)
21. Fung HK, Rao S, Floudas CA, Prokopyev O, Pardalos PM, et al. (2005) Computational comparison studies of quadratic assignment like formulations for the in silico sequence selection problem in de novo protein design. J Comb Optim 10: 41-60. (Pubitemid 41205696)
22. Fung HK, Taylor MS, Floudas CA (2007) Novel formulations for the sequence selection problem in de novo protein design with flexible templates. Optim Method Softw 22: 51-71. (Pubitemid 44878958)
23. Fung HK, Floudas CA, Taylor MS, Zhang L, Morikis D (2008) Toward fullsequence de novo protein design with flexible templates for human betadefensin-2. Biophys J 94: 584-599.
24. Bellows ML, Fung HK, Floudas CA, López de Victoria A, Morikis D (2010) New compstatin variants through two de novo protein design frameworks. Biophys J 98: 2337-2346.
25. Bellows ML, Taylor MS, Cole PA, Shen L, Siliciano RF, et al. (2010) Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. Biophys J 99: 3445-3453.
26. Bellows-Peterson ML, Fung HK, Floudas CA, Kieslich CA, Zhang L, et al. (2012) De novo peptide design with C3a receptor agonist and antagonist activities: Theoretical predictions and experimental validation. J Med Chem 55: 4159-4168.
27. Qian C, Wang X, Manzur K, Sachchidanand, Farooq A, et al. (2006) Structural insights of the specificity and catalysis of a viral histone H3 lysine 27 methyltransferase. J Mol Biol 359: 86-96.
28. Hubbard SJ, Thornton JM (1993) Naccess version 2.1.1. Computer Program, Department of Biochemistry and Molecular Biology, University College London.
29. Rajgaria R, McAllister SR, Floudas CA (2008) Distance dependent centroid to centroid force fields using high resolution decoys. Proteins 70: 950-970. (Pubitemid 351161953)
30. Guntert P, Mumenthaler C, Wuthrich K (1997) Torsion angle dynamics for NMR structure calculation with the new program DYANA. J Mol Biol 273: 283-298. (Pubitemid 27460230)
31. Guntert P (2004) Automated NMR structure calculation with CYANA. Methods Mol Biol 278: 353-378.
32. Ponder J (1998) TINKER, software tools for molecular design. 1998. Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine: St. Louis, MO.
33. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, et al. (1995) A 2nd generation force-field for the simulation of proteins, nucleic-acids, and organicmolecules. J Am Chem Soc 117: 5179-5197.
34. Lilien RH, Stevens BW, Anderson AC, Donald BR (2005) A novel ensemblebased scoring and search algorithm for protein redesign and its application to modify the substrate specificity of the gramicidin synthetase a phenylalanine adenylation enzyme. J Comput Biol 12: 740-761. (Pubitemid 41170479)
35. Lee MR, Baker D, Kollman PA (2001) 2.1 and 1.8 A Ca RMSD structure predictions on two small proteins, HP-36 and S15. J Am Chem Soc 123: 1040-1046. (Pubitemid 32148171)
36. Rohl CA, Baker D (2002) De novo determination of protein backbone structure from residual dipolar couplings using rosetta. J Am Chem Soc 124: 2723-2729. (Pubitemid 34251782)
37. Rohl CA, Strauss CEM, Misura KMS, Baker D (2004) Protein structure prediction using rosetta. Method Enzymol 383: 66-93. (Pubitemid 38401787)
38. DiMaggio PA, McAllister SR, Floudas CA, Feng XJ, Rabinowitz JD, et al. (2008) Biclustering via optimal re-ordering of data matrices in systems biology: Rigorous methods and comparative studies. BMC Bioinformatics 9: 458.
39. DiMaggio PA, McAllister SR, Floudas CA, Feng XJ, Rabinowitz JD, et al. (2010) A network flow model for biclustering via optimal re-ordering of data matrices. J Global Optim 47: 343-354.
40. Daily MD, Masica D, Sivasubramanian A, Somarouthu S, Gray JJ (2005) CAPRI rounds 3-5 reveal promising successes and future challenges for RosettaDock. Proteins 60: 181-186. (Pubitemid 40934884)
41. Gray JJ, Moughon S, Wang C, Schueler-Furman O, Kuhlman B, et al. (2003) Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J Mol Biol 331: 281-299. (Pubitemid 36870793)
42. Gray JJ, Moughon SE, Kortemme T, Schueler-Furman O, Misura KMS, et al. (2003) Proteinprotein docking predictions for the CAPRI experiment. Proteins 52: 118-122. (Pubitemid 36648860)
43. Kuhlman B, Baker D (2000) Native protein sequences are close to optimal for their structures. P Natl Acad Sci USA 97: 10383-10388.
44. Zee BM, Levin RS, Xu B, LeRoy G, Wingreen NS, et al. (2010) In vivo residuespecific histone methylation dynamics. J Biol Chem 285: 3341-3350.
45. Fischle W (2005) In nucleo enzymatic assays for the identification and characterization of histone modifying activities. Methods 36: 362-367. (Pubitemid 41188067)
46. Plazas-Mayorca MD, Zee BM, Young NL, Fingerman IM, LeRoy G, et al. (2009) One-pot shotgun quantitative mass spectrometry characterization of histones. J Proteome Res 8: 5367-5374.
47. Margueron R, Li G, Sarma K, Blais A, Zavadil J, et al. (2008) EZH1 and EZH2 maintain repressive chromatin through different mechanisms. Mol Cell 32: 503-518.
48. Frye SV (2010) The art of the chemical probe. Nat Chem Biol 6: 159-161.